Publication:
Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab

dc.contributor.buuauthorPekbak, Gülseren
dc.contributor.buuauthorPEKBAK, GÜLSEREN
dc.contributor.buuauthorEdiger, Dane
dc.contributor.buuauthorERBAY, MÜGE
dc.contributor.buuauthorGünaydın, Fatma Esra
dc.contributor.buuauthorGÜNAYDIN, FATMA ESRA
dc.contributor.buuauthorErbay, Müge
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Alerji ve İmmunoloji Anabilim Dalı.
dc.contributor.orcid0000-0002-2954-4293
dc.contributor.orcid0000-0002-9268-1071
dc.contributor.researcheridHJA-1363-2022
dc.date.accessioned2024-10-04T05:45:18Z
dc.date.available2024-10-04T05:45:18Z
dc.date.issued2023-01-01
dc.description.abstractCan omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumabIntroduction: Omalizumab, a humanized monoclonal anti-IgE antibody, has largely demonstrated its efficacy in severe allergic asthma. There are limited data about the effectiveness of omalizumab in patients with non-atopic severe persistent asthma. In this study, we aimed to determine the effect of omalizumab in patients with non-atopic severe asthma and compare the data obtained with those in patients with allergic severe asthma.Materials and Methods: This study was an observational, retrospective, tertiary single-center study that assessed and compared the clinical outcome of adult patients with severe asthma (165 atopic and 41 non-atopic) who have been on omalizumab for one year or longer between January 2008 and January 2020. Effectiveness was assessed by considering symptom scores (GINA symptom control score), daily systemic corticosteroids (SCS) dosage, blood eosinophil counts, pulmonary function, and number of severe exacerbations and hospitalizations within the last one year.Results: Omalizumab exhibited significant improvement in the clinical status of non-atopic asthma patients as measured by GINA symptom score [decreased from 3.77 +/- 0.63 to 1.36 +/- 1.27 (p< 0.001)], the number of emergency room visits for asthma [decreased from 11.25 +/- 14.69 to 0.25 +/- 0.55 (p< 0.001)], and the number of hospitalizations [decreased from 1.17 +/- 2.87 to 0.14 +/- 0.36 (p= 0.036)]. These results were not significantly different from those obtained in allergic asthma patients. FEV1 improved significantly from 2.08 +/- 0.86 to 2.14 +/- 0.84 (p= 0.041) and oral corticosteroid doses decreased significantly from 1.67 +/- 7.49 to 0.46 +/- 2.74 (p= 0.015) in the only atopic group.Conclusion: Omalizumab, which is a proven and effective treatment option for allergic asthma, may also be an efficacious alternative option in non-atopic severe asthma.
dc.identifier.doi10.5578/tt.20239904
dc.identifier.endpage33
dc.identifier.issn0494-1373
dc.identifier.issue1
dc.identifier.startpage24
dc.identifier.urihttps://doi.org/10.5578/tt.20239904
dc.identifier.urihttps://hdl.handle.net/11452/45831
dc.identifier.volume71
dc.identifier.wos000957606300004
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherTurkish Assoc Tuberculosis & Thorax
dc.relation.journalTuberkuloz Ve Toraks-tuberculosis And Thorax
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.subjectSevere allergic-asthma
dc.subjectNonallergic asthma
dc.subjectLung-function
dc.subjectIge
dc.subjectTrial
dc.subjectAsthma
dc.subjectImmunoglobulin e
dc.subjectBiologic agents
dc.subjectOmalizumab
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectRespiratory system
dc.titleCan omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationf9b08ee2-eb50-4709-b054-fd10d2113a8c
relation.isAuthorOfPublicationac2fa17e-3bc4-46f9-be14-9e025b55a6d7
relation.isAuthorOfPublicationb7ea92c7-30ca-4a4c-8906-b328d5ed0479
relation.isAuthorOfPublication.latestForDiscoveryf9b08ee2-eb50-4709-b054-fd10d2113a8c

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ediger_vd_2023.pdf
Size:
153.08 KB
Format:
Adobe Portable Document Format

Collections